Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | KMO | O15229 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | METAP2 | P50579 | 1/20 | 0.47 |
| ▸ | PFKFB3 | Q16875 | 3/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.44 |
| ▸ | SDHB | P21912 | 1/20 | 0.43 |
| ▸ | VCP | P55072 | 1/20 | 0.43 |
| ▸ | ATP4A | P20648 | 1/20 | 0.42 |
| ▸ | ATP4B | P51164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12264969 | 0.90 | XDH (0.53) | RAB9AKDM4ENPC1XDHKMO | |
| SCHEMBL9920499 | 0.88 | TSHR (0.42) | RAB9AKDM4ENPC1 | |
| SCHEMBL17051653 | 0.85 | KMT2A (0.53) | RAB9AKDM4ENPC1XDHKMO | |
| SCHEMBL3851837 | 0.82 | RAB9A (0.58) | RAB9AKDM4ENPC1XDHKMO | |
| SCHEMBL14970094 | 0.82 | TSHR (0.56) | RAB9AKDM4ENPC1 | |
| SCHEMBL17051671 | 0.81 | LMNA (0.56) | RAB9AKDM4ENPC1XDHKMO | |
| SCHEMBL28636416 | 0.81 | HSD17B2 (0.52) | METAP2PFKFB3 | |
| SCHEMBL1358738 | 0.81 | RAB9A (0.61) | RAB9AKDM4ENPC1XDHKMO | |
| SCHEMBL19397318 | 0.81 | KMT2A (0.54) | RAB9AKDM4ENPC1XDHENPP3 | |
| SCHEMBL603720 | 0.81 | XDH (0.46) | RAB9AKDM4ENPC1XDHKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362246-B2 | Bispyrimidines for electronic applications | BASF SE (DE) | 2013-01-29 | — | — | US | disclosed |
| US-20120149904-A1 | BISPYRIMIDINES FOR ELECTRONIC APPLICATIONS | BASF SE (DE) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149904-A1 | BISPYRIMIDINES FOR ELECTRONIC APPLICATIONS | DPYD, TYMP, TYMS | RAB9A 2237/4885KDM4E 1622/4885NPC1 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.